CD38 and plasma cell myeloma: Additionally, patients with penta-refractory myeloma (myeloma refractory to lenalidomide, pomalidomide, bortezomib, carfilzomib and an anti-CD38 MoAb) have an even more grim prognosis with a median OS of about 6 months with subsequent therapies (5–7).